Impact of Sarcopenia in Healthy Aging and Suggested Interventions

  • Tuğba Erdoğan
  • Gülistan Bahat
  • Mehmet Akif Karan


Sarcopenia is a condition characterized by loss of skeletal muscle mass and function with aging and is associated with frailty, physical disability, falls, and higher mortality.

Many factors play role in the pathophysiology of sarcopenia. These include genetic factors, mitochondrial defects, decreased anabolic hormones, inflammatory cytokines, insulin resistance, decreased protein intake and activity, poor blood flow to muscle, and growth-derived factor-11 deficiency. The molecular mechanisms underlying and/or associated with sarcopenia have significant role in aging. Hence, interventions targeting sarcopenia shall have an impact on healthy aging. At present, the best-demonstrated and practically recommended approaches to prevent/treat sarcopenia are resistance exercises and intake of adequate protein and vitamin D. Adequate intake of protein and resistance exercises are mandatory to preserve muscle mass. Many other promising treatment modalities are currently being investigated listed on the way.


Aging Intervention Molecular mechanisms Sarcopenia 


  1. Amold A-S, Egger A, Handschin C (2011) PGC-1 α and myokines in the aging muscle-a mini-review. Gerontology 57:37–43CrossRefGoogle Scholar
  2. Attie KM, Brogstein NG, Yang Y et al (2013) A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve 47:416–423CrossRefGoogle Scholar
  3. Bahat G, Tufan A, Tufan F et al (2016) Cut-off points to identify sarcopenia according to European Working Group on Sarcopenia in Older People (EWGSOP) definition. Clin Nutr 35(6):1557–1563CrossRefGoogle Scholar
  4. Basario S, Collins L, Dillon EL et al (2013) The safety, pharmacokinetics, and effects of LGD- 4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A 68:87–95CrossRefGoogle Scholar
  5. Baumgartner RN, Koehler KM, Gallagher D et al (1998) Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147(8):755–763CrossRefGoogle Scholar
  6. Baumgartner RN, Waters D, Gallagher D et al (1999) Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev 107:123–113CrossRefGoogle Scholar
  7. Bhasin S, Woodhouse L, Casaburi R et al (2005) Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrniol Metab 90:678–688CrossRefGoogle Scholar
  8. Bhattacharyya GS, Julka PK, Bondarde S et al (2013) Phase II study evaluating safety and efficacy of co-administering propranolol and etodolac for treating cancer cachexia in geriatric patients. J Geriatr Oncol 4:S38CrossRefGoogle Scholar
  9. Bischoff HA, Borchers M, Gudat F et al (2001) In situ detection of 1,25-dihydroxyvitamin D3 receptor in human skeletal muscle tissue. Histochem J 33(1):19–24CrossRefGoogle Scholar
  10. Borst SE, Shuster JJ, Zou B et al (2014) Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis. BMC Med 12:211–215CrossRefGoogle Scholar
  11. Budoff MJ, Ellenberg SS, Lewis CE et al (2017) Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA 317(7):708–716CrossRefGoogle Scholar
  12. Burton LA, Sumukadas D (2010) Optimal management of sarcopenia. Clin Interv Aging 5:217–228PubMedPubMedCentralGoogle Scholar
  13. Calder PC (2013) Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br J Clin Pharmacol 75(3):645–662CrossRefGoogle Scholar
  14. Carona G, Maseroli E, Rastrelli G (2014) Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf 13:1327–1351CrossRefGoogle Scholar
  15. Cawthon PM, Peters KW, Shardell MD et al (2014) Cutpoints for low appendicular lean mass that identify older adults with clinically significant weakness. J Gerontol A Biol Sci Med Sci 69:567–575CrossRefGoogle Scholar
  16. Chapman IM, Visvanathan R, Hammond AJ et al (2009) Effect of testosterone and a nutritional supplement, alone and in combination, on hospital admissions in undernourished older men and women. Am J Clin Nutr 89:880–889CrossRefGoogle Scholar
  17. Chasen M, Hirschman SZ, Bhargava R (2011) Phase II study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexia/cachexia. J Am Med Dir Assoc 12:62–67CrossRefGoogle Scholar
  18. Cheetham TC, An JJ, Jacobsen SJ et al (2017) Association of testosterone replacement with cardiovascular outcomes among men with androgen deficiency. JAMA Intern Med 177(4):491–499CrossRefGoogle Scholar
  19. Cohen S, Zhai B, Gygi SP et al (2012) Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments in muscle atrophy. J Cell Biol 198:575–589CrossRefGoogle Scholar
  20. Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al (2010) Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 39:412–423CrossRefGoogle Scholar
  21. Cruz-Jentoft AJ, Landi F, Schneider SM et al (2014) Prevalence of and interventions for sarcopenia in ageing adults: a systemic review. Report of the international Sarcopenia İnitiative (EWGSOP and IWGS). Age Ageing 43(6):748–759CrossRefGoogle Scholar
  22. Dalton JT, Barnette KG, Bohl CE et al (2011) The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachex Sarcopenia Muscle 2:153–161CrossRefGoogle Scholar
  23. Dam TT, Peters KW, Fragala M et al (2014) An evidence-based comparison of operational criteria for the presence of sarcopenia. J Gerontol A Biol Sci Med Sci 69(5):584–590CrossRefGoogle Scholar
  24. Demontis F, Piccirillo R, Goldberg AL et al (2013) The influence of skeletal muscle on systemic aging and lifespan. Aging Cell 12:943–949CrossRefGoogle Scholar
  25. Deutz NE, Bauer JM, Barazzoni R et al (2014) Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN Expert Group. Clin Nutr 33(6):929–936CrossRefGoogle Scholar
  26. Fajardo RJ, Manoharan RK, Pearsall RS et al (2010) Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis). Bone 46:64–71CrossRefGoogle Scholar
  27. Farooqi V, van den Berg ME, Cameron ID et al (2014) Anabolic steroids for rehabilitation after hip fracture in older people. Cochrane Database Syst Rev 10:CD008887Google Scholar
  28. Ferrando AA, Sheffield-Moore M, Paddon-Jones D et al (2003) Differential anabolic effects of testosterone and amino acid feeding in older men. J Clin Endocrinol Metab 88:358–362CrossRefGoogle Scholar
  29. Fielding RA, Vellas B, Evans WJ et al (2011) Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International Working Group on Sarcopenia. J Am Med Dir Assoc 12:249–256CrossRefGoogle Scholar
  30. Fried LP, Tangen CM, Walston J et al (2001) Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56(3):M146e56CrossRefGoogle Scholar
  31. Garatachea N, Lucia A (2013) Genes and the ageing muscle: a review on genetic association studies. Age 35:207–233CrossRefGoogle Scholar
  32. Gariballa S, Alessa A (2013) Sarcopenia: prevalence and prognostic significance in hospitalized patients. Clin Nutr 32:772–776CrossRefGoogle Scholar
  33. Hansen R, Saikali KG, Chou W et al (2014) Tirasemtiv amplifies skeletal muscle response to nerve activation in humans. Muscle Nerve 50(6):925–931CrossRefGoogle Scholar
  34. Harrison C, Kiladjian J-J, Al-Ali HK et al (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787–798CrossRefGoogle Scholar
  35. Houston DK, Nicklas BJ, Ding J et al (2008) Health ABC Study. Dietary protein intake is associated with lean mass change in older, community-dwelling adults: the Health, Aging, and Body Composition (Health ABC) Study. Am J Clin Nutr 87(1):150–155CrossRefGoogle Scholar
  36. Hutcheon SD, Gillespie ND, Crombie IK et al (2002) Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: a randomized double blind placebo controlled trial. Heart 88:373–377CrossRefGoogle Scholar
  37. Irwig MS (2014) Bone health in hypogonadal men. Curr Opin Urol 24:608–613CrossRefGoogle Scholar
  38. Janssen I, Heymsfield SB, Ross R (2002) Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 50(5):889e96CrossRefGoogle Scholar
  39. Karakelides H, Nair KS (2005) Sarcopenia of aging and its metabolic impact. Curr Top Dev Biol 68:123e148Google Scholar
  40. Kittiskulnam P, Carrero JJ, Chertow GM et al (2017) Sarcopenia among patients receiving hemodialysis: weighing the evidence. J Cachexia Sarcopenia Muscle 8(1):57–68CrossRefGoogle Scholar
  41. Koopman R, Verdijk LB, Van Loon LJC (2010) Exercise and nutritional interventions to combat age-related muscle loss sarcopenia – age-related muscle wasting and weakness. pp 289–315Google Scholar
  42. Kovacheva EL, Hikim AP, Shen R et al (2010) Testosterone supplementation reverses sarcopenia in aging through regulation of myostatin, c-Jun NH2-terminal kinase, Notch, and Akt signaling pathways. Endocrniology 151:628–638CrossRefGoogle Scholar
  43. Landi F, Liperoti R, Fusco D et al (2012) Prevalence and risk factors of sarcopenia among nursing home older residents. J Gerontol A Biol Sci Med Sci 67:48–55CrossRefGoogle Scholar
  44. Landi F, Cruz-Jentoft AJ, Liperoti R et al (2013) Sarcopenia and mortality risk in frail older persons aged 80 years and older: results from ilSIRENTE study. Age Ageing 42:203–209CrossRefGoogle Scholar
  45. Laurentani F, Russo C, Bandinelli S et al (2003) Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. J Appl Physiol 95:1851–1860CrossRefGoogle Scholar
  46. Layman DK (2009) Dietary guidelines should reflect new understandings about adult protein needs. Nutr Metab 6:12. CrossRefGoogle Scholar
  47. Macdonald JH, Marcora SM, Jibani MM et al (2007) Nandrolone decanoate as anabolic therapy in chronic kidney disease: a randomized phase II dose-finding study. Nephron Clin Pract 106:c125–c135CrossRefGoogle Scholar
  48. Malik F, Hwee D, Kennedy A et al (2014) Fast skeletal muscle troponin activator Tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model. Neurology 82(10 Supplement):1.081Google Scholar
  49. Marzetti E, Calvani R, Cesari M et al (2013) Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials. Int J Biochem Cell Biol 45:2288–2301CrossRefGoogle Scholar
  50. Mogentaler A, Miner MM, Caliber M et al (2015) Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc 90:224–251CrossRefGoogle Scholar
  51. Mohler ML, Bohl CE, Jones A et al (2009) Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem 52:3598–3617CrossRefGoogle Scholar
  52. Morley JE (2011) Should frailty be treated with testosterone? Aging Male 14:1–3CrossRefGoogle Scholar
  53. Morley JE (2016) Pharmacologic options for the treatment of sarcopenia. Calcif Tissue Int 98:319–333CrossRefGoogle Scholar
  54. Morley JE, Kaiser F, Perry HM et al (1997) Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 46:410–413CrossRefGoogle Scholar
  55. Morley JE, Abbatecola AM, Argiles JM et al (2011) Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc 12(6):403–409CrossRefGoogle Scholar
  56. Mowe M, Haug E, Bohmer T (1999) Low serum calcidiol concentration in older adults with reduced muscular function. J Am Geriatr Soc 47(2):220–226CrossRefGoogle Scholar
  57. Muscaritoli M, Anker SD, Argiles J et al (2010) Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr 29(2):154–159CrossRefGoogle Scholar
  58. Narkar VA, Downes M, Yu RT et al (2008) AMPK and PPARdelta agonists are exercise mimetics. Cell 134(3):405–415CrossRefGoogle Scholar
  59. Nass R, Pezzoli SS, Oliveri MC et al (2008) Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 149:601–611CrossRefGoogle Scholar
  60. Nieschlag E (2015) Current topics in testosterone replacement of hypogonadal men. Best Pract Res Clin Endocrinol Metab 29:77–90CrossRefGoogle Scholar
  61. Orwoll E (2017) Further elucidation of the potential benefits of testosterone therapy in older men. JAMA Intern Med 177(4):459–460CrossRefGoogle Scholar
  62. Padhi D, Higano CS, Shore ND et al (2014) Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 99:E1967–E1975CrossRefGoogle Scholar
  63. Papadakis MA, Grady D, Black D et al (1996) Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med 124(8):708–716CrossRefGoogle Scholar
  64. Papanicolaou DA, Ather SN, Zhu H et al (2013) A phase IIA randomized, placebo- controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia. J Nutr Health Aging 17:533–543CrossRefGoogle Scholar
  65. Peters R, Beckett N, Burch L et al (2010) The effect of treatment based on diuretic (indapamide) ± ACE inhibitor (perindopril) on fractures in the hypertension in the very elderly trial (HYVET). Age Ageing 39:609–616CrossRefGoogle Scholar
  66. Phu S, Boersma D, Duque G (2015) Exercise and sarcopenia. J Clin Densitom 18(4):488–492CrossRefGoogle Scholar
  67. Pistilli EE, Quinn LS (2013) From anabolic to oxidative: reconsidering the roles of IL-15 and IL-15Ra in skeletal muscle. Exerc Sport Sci Rev 41:100–110CrossRefGoogle Scholar
  68. Potsch MS, Tschirner A, Palus S, Springer J (2014) The anabolic catabolic transforming agenda (ACTA) espindolol increases muscle mass and decreases fat mass in old rats. J Cachexia Sarcopenia Muscle 5:149–158CrossRefGoogle Scholar
  69. Purves-Smith FM, Sgarioto N, Hepple RT (2014) Fiber typing in aging muscle. Exerc Sport Sci Rev 42:45–52CrossRefGoogle Scholar
  70. Resnick SM, Matsumoto AM, Stephens-Shields AJ et al (2016) Testosterone treatment and sexual function in older men with low testosterone levels. J Clin Endocrinol Metab 101:3096CrossRefGoogle Scholar
  71. Rooks D, Praestgaard J, Hariry S et al (2017) Treatment of sarcopenia with Bimagrumab: results from a phase II, randomized, controlled, proof-of-concept study. J Am Geriatr Soc 65(9):1988–1995CrossRefGoogle Scholar
  72. Rosenberg IH, Roubenoff R (1995) Stalking sarcopenia. Ann Intern Med 123:727e728CrossRefGoogle Scholar
  73. Short KR, Vıttone JL, Bıgelow ML et al (2004) Age and aerobic exercise training effects on whole body and muscle protein metabolism. Am J Physiol Endocrinol Metab 286:E92–E101CrossRefGoogle Scholar
  74. Shuler FD, Wingate MK, Moore GH et al (2012) Sports health benefits of vitamin D. Sports Health 4(6):496–501CrossRefGoogle Scholar
  75. Steiner MS (2013) Enobosarm, a selective androgen receptor modulator, increases lean body mass in advanced non-small cell lung cancer patients in two pivotal, international phase 3 trials. J Cachexia Sarcopenia Muscle 4:69. CrossRefGoogle Scholar
  76. Stephanie T, Page John K, Amory F et al (2005) Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 90(3).1):1502–1510CrossRefGoogle Scholar
  77. Steward Coats AJ, Srinivasan Surendran J, Chicarmana H et al (2011) The ACT-ONE trial, a multicenter, randomized, double-blind, placebo-controlled dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design. J Cachexia Sarcopenia Muscle 2:201–207CrossRefGoogle Scholar
  78. Stratos I, Li Z, Herlyn P et al (2013) Vitamin D increases cellular turnover and functionally restores the skeletal muscle after crush injury in rats. Am J Pathol 182(3):895–904CrossRefGoogle Scholar
  79. Sullivan DH, Carter WJ, Warr WR et al (1998) Side effects resulting from the use of growth hormone and insulin-like growth factor-1 as combined therapy to frail elderly patients. J Gerontol A 53:M183–M187CrossRefGoogle Scholar
  80. Sumukadas D, Witham MD, Struthers AD et al (2007) Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. CMAJ 177:867–874CrossRefGoogle Scholar
  81. Sumukadas D, Witham MD, Struthers AD et al (2008) Ace inhibitors as a therapy for sarcopenia-evidence and possible mechanisms. Nutr Health Aging 12(7):480–485CrossRefGoogle Scholar
  82. Supasyndh O, Satirapoj B, Aramwit P et al (2013) Effect of oral anabolic steroid on muscle strength and muscle growth in hemodialysis patients. Clin J Am Soc Nephrol 8(2):271–279CrossRefGoogle Scholar
  83. Tanimoto Y, Watanabe M, Sun W et al (2012) Association between sarcopenia and higher-level functional capacity in daily living in community-dwelling elderly subjects in Japan. Arch Gerontol Geriatr 55:9–13CrossRefGoogle Scholar
  84. Verstovsek S, Kantarjian H, Mesa RA et al (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363(12):1117–1127CrossRefGoogle Scholar
  85. Visser M, Schaap LA (2011) Consequences of sarcopenia. Clin Geriatr Med 27(3):387–399CrossRefGoogle Scholar
  86. Wagner KR, Fleckenstein JL, Amato AA et al (2008) A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 63:561–571CrossRefGoogle Scholar
  87. White HK, Petrie CD, Landschulz W et al (2009) Capromorelin Study Group: effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab 94:1198–1206CrossRefGoogle Scholar
  88. Wittert GA, Chapman IM, Haren MT et al (2003) Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A 58:618–625CrossRefGoogle Scholar
  89. Ziambaras K, Dagogo-Jack S et al (1997) Reversible muscle weakness in patients with vitamin D deficiency. West J Med 167(6):435–439PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Tuğba Erdoğan
    • 1
  • Gülistan Bahat
    • 1
  • Mehmet Akif Karan
    • 1
  1. 1.Department of Internal Medicine, Division of Geriatrics, Istanbul Medical SchoolIstanbul UniversityIstanbulTurkey

Personalised recommendations